These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 37490292)

  • 1. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.
    García-Pardo M; Czarnecka-Kujawa K; Law JH; Salvarrey AM; Fernandes R; Fan ZJ; Waddell TK; Yasufuku K; Liu G; Donahoe LL; Pierre A; Le LW; Gunasegaran T; Ghumman N; Shepherd FA; Bradbury PA; Sacher AG; Schmid S; Corke L; Feng J; Stockley T; Pal P; Rogalla P; Pipinikas C; Howarth K; Ambasager B; Mezquita L; Tsao MS; Leighl NB
    JAMA Netw Open; 2023 Jul; 6(7):e2325332. PubMed ID: 37490292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical Trial.
    Xu J; Liu Z; Bai H; Dong G; Zhong J; Wan R; Zang A; Li X; Li Q; Guo J; Du N; Zhong D; Huang Y; Lv Q; Zhang J; Zhao Y; Gao L; Li L; Zhang C; Zhao J; Li B; Liu Z; Yang Z; Ji D; Wang T; Duan J; Wang Z; Wang J
    JAMA Oncol; 2022 Sep; 8(9):1328-1332. PubMed ID: 35862035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy.
    Garcia-Pardo M; Czarnecka K; Law JH; Salvarrey A; Fernandes R; Fan J; Corke L; Waddell TK; Yasufuku K; Donahoe LL; Pierre A; Le LW; Ghumman N; Liu G; Shepherd FA; Bradbury P; Sacher A; Stockley T; Pal P; Rogalla P; Tsao MS; Leighl NB
    Ther Adv Med Oncol; 2022; 14():17588359221126151. PubMed ID: 36158638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Dong S; Wang Z; Zhang JT; Yan B; Zhang C; Gao X; Sun H; Li YS; Yan HH; Tu HY; Liu SM; Gong Y; Gao W; Huang J; Liao RQ; Lin JT; Ke EE; Xu Z; Zhang X; Xia X; Li AN; Liu SY; Pan Y; Yang JJ; Zhong WZ; Yi X; Zhou Q; Yang XN; Wu YL
    JAMA Oncol; 2024 Jul; 10(7):932-940. PubMed ID: 38869865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.
    Iams WT; Mackay M; Ben-Shachar R; Drews J; Manghnani K; Hockenberry AJ; Cristofanilli M; Nimeiri H; Guinney J; Benson AB
    JAMA Netw Open; 2024 Jan; 7(1):e2351700. PubMed ID: 38252441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.
    Prabhash K; Biswas B; Khurana S; Batra U; Biswas G; Advani SH; Mohapatra PN; Rajappa S; Sharma A; Patil S; Dattatreya PS; Roy R; Almel S; Goyal G; Warrier N
    Indian J Cancer; 2022 Mar; 59(Supplement):S11-S18. PubMed ID: 35343188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
    Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB
    Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
    Sabari JK; Offin M; Stephens D; Ni A; Lee A; Pavlakis N; Clarke S; Diakos CI; Datta S; Tandon N; Martinez A; Myers ML; Makhnin A; Leger Y; Yu HA; Paik PK; Chaft JE; Kris MG; Jeon JO; Borsu LA; Ladanyi M; Arcila ME; Hernandez J; Henderson S; Shaffer T; Garg K; DiPasquo D; Raymond CK; Lim LP; Li M; Hellmann MD; Drilon A; Riely GJ; Rusch VW; Jones DR; Rimner A; Rudin CM; Isbell JM; Li BT
    J Natl Cancer Inst; 2019 Jun; 111(6):575-583. PubMed ID: 30496436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer.
    Lin Z; Li Y; Tang S; Deng Q; Jiang J; Zhou C
    Lung Cancer; 2023 Aug; 182():107282. PubMed ID: 37392713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Pritchett MA; Camidge DR; Patel M; Khatri J; Boniol S; Friedman EK; Khomani A; Dalia S; Baker-Neblett K; Plagnol V; Howarth KD; Jones GR; Rosenfeld N; Morris CD; Govindan R
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Assessment of Complementary Liquid Biopsy on Tissue Single-Gene Testing for Tumor Genotyping in Advanced NSCLC.
    Desmeules P; Dusselier M; Bouffard C; Bafaro J; Fortin M; Labbé C; Joubert P
    Curr Oncol; 2023 Jan; 30(1):575-585. PubMed ID: 36661694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.